CLC bio acquires software company Molegro
Plans to invest significant resources into the continued development of the acquired protein-ligand docking and data modelling software
Danish bioinformatics solution provider CLC bio has acquired Molegro, a specialised software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor, and determination of molecule similarity. The financial terms of the transaction were not disclosed.
‘Since 2005, Molegro has demonstrated the ability to develop and support superior molecular docking products. We look forward to adding the very talented people from Molegro to our team at CLC bio,’ said CEO at CLC bio, Thomas Knudsen. ‘This acquisition underlines our dedication to always look for the most viable ways to enhance our analysis platform for the benefit of our customers.’
In the coming years, CLC bio will invest significant resources into the continued development of the acquired protein-ligand docking and data modelling software. Effective immediately, Molegro will become part of CLC bio's organisation at its headquarters in Aarhus, Denmark.
‘We have always had a strong focus on the science behind our software, and joining CLC bio allows us to become part of a strong analysis platform and focus even more on developing the next generation of molecular docking products,’ added Dr René Thomsen, CEO at Molegro. ‘CLC bio has demonstrated the capability to build an elaborate analysis platform and distribute it internationally, and that competence is the best way to take the features of Molegro's software to the next level.’
